Alteration in Timing of Plerixafor Administration

Exclusion Criteria

• •1. High risk co-morbidities for acute treatment complications (e.g., symptomatic coronary artery disease)
• •2. Brain metastases or carcinomatous meningitis
• •3. Previous treatment with high dose chemotherapy and autologous transplant.
• •4. Previous attempt to collect B-HPCs following mobilization with growth factors alone, growth factors and chemotherapy, or plerixafor and growth factors.
• •5. Acute infection or unexplained fever \>38°C
• •6. Weight \> 175% of ideal body weight as defined by the Devine equation.
• •7. Experimental therapy within 4 weeks
• •8. Cytokine administration in the previous 14 days